# US 9,750,747 B2 · Treatments involving eslicarbazepine acetate or eslicarbazepine > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 9,750,747 B2 - Document ID: US9750747B2 - Status: Granted - Kind: B2 - Application number: 14/240,847 - Filed: 2012-08-24 - Published: 2014-10-23 - Granted: 2017-09-05 - Earliest claimed: 2011-08-26 - Assignees: Bail-Portela & Ca, S.A. - Applicants: Patricio Manuel Vieira Araujo Soares Da Silva - Inventors: Patricio Manuel Vieira Araujo Soares Da Silva - Web page: https://patentgrep.com/patent/US9750747B2 ## CPC - A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole - A61K 31/195: having an amino group - A61K 31/4166: having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin - A61K 31/4535: containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen - A61K 31/515: Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61P 25/00: Drugs for disorders of the nervous system - A61P 25/04: Centrally acting analgesics, e.g. opioids - A61P 25/08: Antiepileptics; Anticonvulsants - A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The invention provides a drug selected from eslicarbazepine acetate and eslicarbazepine, for use in treating or preventing a disorder selected from epilepsy, affective disorders, schizoaffective disorders, bipolar disorders, neuropathic pain and neuropathic pain related disorders, attention disorders, anxiety disorders, sensorimotor disorders, vestibular disorders, and fibromyalgia, in a patient suffering from or susceptible to absence seizures. ## Claims ### Claim 1 A method of treating partial-onset seizures in a patient who is suffering from or susceptible to absence seizures, which method comprises: administering to said patient a safe and effective amount of eslicarbazepine acetate. ### Claim 2 (depends on 1) The method according to claim 1, wherein the patient is female. ### Claim 3 (depends on 1) The method according to claim 1, wherein the patient is under sixteen years of age. ### Claim 4 (depends on 1) The method according to claim 1, wherein the patient has not reached puberty. ### Claim 5 (depends on 1) The method according to claim 1, wherein the patient has previously suffered from at least one seizure selected from the group consisting of absence seizure, myoclonic seizure and tonic-clonic seizure. ### Claim 6 (depends on 1) The method according to claim 1, wherein the patient has a family history of epilepsy. ### Claim 7 (depends on 1) The method according to claim 1, wherein the patient has the R43Q mutation in the γ-aminobutyric acid (GABA)A receptor γ-2 subunit. ### Claim 8 (depends on 1) The method according to claim 1, wherein the patient is suffering from or susceptible to at least one disease or syndrome selected from the group consisting of: childhood absence epilepsy, juvenile absence epilepsy, myoclonic absence epilepsy, juvenile myoclonic epilepsy, Lennox Gastaut syndrome, perioral myoclonus with absences, Jeavons syndrome and idiopathic generalized epilepsy with phantom absences. ### Claim 9 (depends on 1) The method according to claim 1, wherein the patient is receiving a second drug which may cause or aggravate absence seizures. ### Claim 10 (depends on 9) The method according to claim 9, wherein the second drug is selected from the group consisting of: carbamazepine, oxcarbazepine, vigabatrin, tiagabine, phenytoin, phenobarbital, gabapentin, and pregabalin. ### Claim 11 (depends on 1) The method according to claim 1, wherein the eslicarbazepine acetate is administered orally. ### Claim 12 (depends on 1) The method according to claim 1, wherein the eslicarbazepine acetate is administered once daily. ### Claim 13 (depends on 1) The method according to claim 1, wherein the patient receives one or more additional medications for treatment of partial-onset seizures. ### Claim 14 (depends on 13) The method according to claim 13, wherein the additional medication is selected from the group consisting of: clorazepate, clonazepam, ethosuximide, felbamate, fosphenytoin, lacosamide, lamotrigine, levetiracetam, primidone, topiramate, valproate semisodium, valproic acid, and zonisamide. ### Claim 15 (depends on 1) The method according to claim 1, wherein the eslicarbazepine acetate is administered to the patient as an adjunct therapy. ### Claim 16 A method of treating partial-onset seizures in a patient who is suffering from or susceptible to absence seizures, which method comprises: administering to said patient a safe and effective amount of a pharmaceutical composition, which comprises a pharmaceutically acceptable carrier and a safe and effective amount of eslicarbazepine acetate as an active ingredient. ### Claim 17 (depends on 16) The method according to claim 16, wherein the pharmaceutical composition is in the form of a tablet, a suspension or a sprinkle formulation. ### Claim 18 A method of treating partial onset seizures, which method comprises: (a) selecting a patient who is suffering from or susceptible to absence seizures; and (b) administering to said patient a safe and effective amount of eslicarbazepine acetate, or a pharmaceutical composition, which comprises a pharmaceutically acceptable carrier and a safe and effective amount of eslicarbazepine acetate as an active ingredient. ### Claim 19 A method of reducing the incidence of absence seizures in a patient, which method comprises administering to said patient a safe and effective amount of eslicarbazepine acetate, or a pharmaceutical composition, which comprises a pharmaceutically acceptable carrier and a safe and effective amount of eslicarbazepine acetate as an active ingredient.